Enterprise of Rosatom State Corporation
Print version

Industry news


Priority Review Given for the Expanded Use of Lymphoseek (Technetium-99m Tilmanocept) Injection

Navidea Biopharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has accepted the Supplemental New Drug Application (sNDA) and granted a Priority Review for the expanded use of Lymphoseek (Technetium-99m tilmanocept) Injection indicated for sentinel lymph node (SLN) detection in patients with head and neck cancer.

Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a June 16 target review date for the Lymphoseek sNDA. The FDA grants priority review status to drug applications that may offer a significant improvement in treatment over existing options. Lymphoseek is currently approved for use in lymphatic mapping procedures performed to aid in the diagnostic evaluation of lymph nodes draining a primary tumor in patients with breast cancer and melanoma.

For more information visit: www.itnonline.com


comments powered by Disqus